Unbound MEDLINE

Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate.

Abstract

BACKGROUND
Sevelamer hydrochloride is a recently approved calcium- and aluminium-free phosphate binder. A randomized study comparing sevelamer and calcium acetate was performed to assess the control of hyperphosphatemia in hemodialysis patients.
METHODS
Administration of phosphate binders was discontinued during a two-week washout period. The patients were then randomized to receive sevelamer or calcium acetate. The laboratory tests were performed monthly for 34 weeks.
RESULTS
There was a statistically significant decrease of serum phosphorus in both sevelamer and calcium acetate treatments. In addition, sevelamer improved the lipid profile.
CONCLUSION
This study confirms that sevelamer is effective at lowering serum phosphorus in hemodialysis patients and that it has several striking properties that could be beneficial in atherosclerosis in dialysis patients.

Links

  • Aggregator Full Text
  • Authors

    Hervás JG, Prados D, Cerezo S

    Source

    Kidney international. Supplement :85 2003 Jun pg S69-72

    MeSH

    Acetates
    Adult
    Aged
    Alkaline Phosphatase
    Calcium
    Calcium Compounds
    Epoxy Compounds
    Female
    Humans
    Kidney Failure, Chronic
    Lipids
    Male
    Middle Aged
    Parathyroid Hormone
    Phosphates
    Phosphorus
    Polyamines
    Polyethylenes
    Renal Dialysis

    Pub Type(s)

    Clinical Trial
    Comparative Study
    Journal Article
    Randomized Controlled Trial
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    12753270